Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: Clinical and outcome implications

Epilepsy and Behavior

Volumn 15, Issue 3, 2009, Pages 372-375

  López Fraile, Isabel P ^a   Cid, Antonio Oliveros ^b   Juste, Antonio Oliveros ^c   Modrego, Pedro J ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL QUIRÓN   (Spain)

^c Policlínica Sagasta ^*  (Spain)

Author keywords

Antiepileptic drugs; Levetiracetam; Placental transfer; Plasma concentrations; Pregnancy; Tetratogenesis

Indexed keywords

CLOBAZAM; ETIRACETAM; LAMOTRIGINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANTHROPOMETRY; ARTICLE; CLINICAL ARTICLE; CONGENITAL MALFORMATION; DELIVERY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG MONITORING; EPILEPSY; FEMALE; GESTATIONAL AGE; HUMAN; PREGNANCY; PUERPERIUM; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; TREATMENT OUTCOME; UMBILICAL CORD;

ADULT; ANTICONVULSANTS; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MATERNAL-FETAL EXCHANGE; PIRACETAM; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS; TRIAZINES;

EID: 67650427126     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2009.04.006     Document Type: Article

References (13)

1. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 43 (2004) 707-724
2. Tomson T., Palm R., Källén K., et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 48 (2007) 1111-1116
3. Pennell P.B., Koganti A., Helmers S., et al. The impact of pregnancy and childbirth on the elimination of levetiracetam. Epilepsia 46 Suppl. 8 (2005) 89
4. Pérez M.I., Castrillo J., Güallar A., and Oliveros A. Evolution of epilepsy in successive pregnancies. Neurología 19 (2004) 301-306
5. Johannessen S.I., and Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?. Clin Pharmacokinet 45 (2006) 1061-1075
6. Pennell P.B. Antiepileptic drug pharmacokinetics during pregnancy and lactation [review]. Neurology 61 Suppl. 2 (2003) S35-S42
7. May T.W., Rambeck B., and Jürgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 25 (2003) 690-699
8. Westin A.A., Reimers A., Helde G., Nakken K.O., and Brodtkorb E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure 17 (2008) 192-198
9. Bernus I., Hooper D., Dickinson R.G., and Eadie M.J. Effects of pregnancy on various pathways of human antiepileptic drug metabolism. Clin Neuropharmacol 20 (1997) 13-21
10. Johannessen S.I., Helde G., and Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia 46 (2005) 775-777
11. Allegaert K., Lewi L., Naulaers G., and Lagae L. Levetiracetam pharmacokinetics in neonates at birth. Epilepsia 47 (2006) 1068-1069
12. Long L. Levetiracetam monotherapy during pregnancy: a case series. Epilepsy Behav 4 (2003) 447-448
13. Ten Berg K., Samren E.B., van Oppen A.C., Engelsman M., and Lindhout D. Levetiracetam use and pregnancy outcome. Reprod Toxicol 20 (2005) 175-178